Atossa Genetics (NASDAQ: ATOS)
The Company-The Story
Today shares of a little known breast cancer company, Atossa Genetics, ( ATOS: Nasdaq), began showing up on stock traders screens all across the trading world as it rose 15% to close at $1.61 with above average trading volume. The company, based in Seattle Washington, is a littleknown company that trades on the NASDAQ small-cap index. This index is where many small companies begin their trading life before they become larger players for investors and traders alike. While this company has not come out with any cancer cures it does however specialize in a small non-invasive procedure to detect the likelihood of a woman developing breast cancer; one of the leading killers of women in the United States of America.
The company markets nipple aspirate fluid (NAF) cytology tests and pharmacogenomics tests. Its medical devices include the ForeCYTE Breast Aspirator and the FullCYTE Breast Aspirator devices that are intended for the collection of NAF for cytological testing at a laboratory.
The company recently partnered with two behemoths in the medical industry: Henry Schein (HSIC: NASDAQ) and Thermo Fisher Scientific (TMO: NYSE) to distribute their products on a wide scale across the US and Europe.
The Competitors/The Problems
Currently there are no publicly traded companies that compete directly with Atossa in the area where they hold many US and European patents. This makes Atossa a pioneer company and has had many battles along the way to gaining ground in its field, both winning some and losing some. One such loss was when they got bad news from the U.S. Food and Drug Administration, which said that the Seattle company’s ForeCyte Breast Aspirator is not cleared for marketing in the U.S.
This battle still remains, however Atossa has stated they are making inroads in getting that clearance needed to full commercialization of the product that clearly can make them a well-known name all across the world in breast health.
Below please see the daily stock price chart indicating some key technical levels. In the stock trading shown from early February 2015 to the present, please note the huge increase in volume. Also note the area of above this level nearing $2.50 with a clear void in stock price to that point. Arrows are shown indicating possible near term price targets if shares show an increase in demand from positive developments from the company.
They received a very positive report written today by Zacks Investment after they reported earnings yesterday which showed a multi-thousand increase percentage wise in revenues quarter over quarter and year over year.
Being a low priced stock and in the bio-tech industry can be both a gift and a curse to a company’s price performance. One thing is for sure; today’s volume and price action sure did open some eyes to this little-known breast cancer company.